Review Article

Histone Deacetylase Inhibitor Therapy in Epithelial Ovarian Cancer

Table 1

Overview of frequently used histone deacetylase inhibitors being available for clinical and research purposes.

Substance groupsDerivativesIsotypeStudy phase

HydroxamatesTrichostatin A (TSA)I, II
Suberoylanilide hydroxamic acid (SAHA, vorinostat)I, II, IVIII
LBH589 (panobinostat)I, II, IVII
PCI24781 (CRA-024781)I, IIbI
LAQ824I, III
PXD101 (belinostat)I, II, IVII
ITF2357I, IIII
SB939UnknownI
JNJ-16241199 (R306465)II
m-carboxycinnamic acid bishydroxamide (CBHA)
Scriptaid
Oxamflatin
Pyroxamide
Cyclic hydroxamic acid containing peptides (CHAPs)

Short chain fatty acidsButyrateI, IIaII
ValproateI, IIaII
AN-9II
OSU-HDAC42

BenzamidesMS-275 (entinostat)1, 2, 3, 9II
MGCD01031, 2, 3, 11II
Pimelic diphenylamide1, 2, 3
M344
N-acetyldinaline (CI-994)II

Cyclic tetrapeptidesApicidineI, II
Trapoxins
HC-toxin
Chlamydocin
Depsipeptide (FR901228 or FK228) (romidepsin)1, 2, 4, 6II

Sulfonamide anilidesN-2-aminophenyl-3-[4-(4-methylbenzenesulfonylamino)-phenyl]-2-propenamide

OthersDepudecin
NDH-51
KD5150Pan-HDACI

Class I: HDAC 1, 2, 3, 8; class IIa: HDAC 4, 5, 7, 9; class IIb: HDAC 1, 2, 3, 8; class III: HDAC 6, 10; class IV: HDAC 11.